SXTC SXT Pharmaceuticals Market Value to Book Value Ratio

sxtchina.com (SXTC) - corporate logo

China SXT Pharmaceuticals (SXTC) is building a closed-loop production cycle for Chinese remedies, integrating the agricultural sector and retail sales to enhance customer retention. This daily price chart confirms the asset's momentum, with its indicator fixed at 0.00. However, liquidity shortages and pressure from PRC regulators create certain challenges. Simultaneously, China SXT Pharmaceuticals (SXTC) is implementing intelligent systems to automate the extraction and packaging of preparations.

sxtchina.com (SXTC) - Market Value to Book Value from 07/04/2022 to 10/29/2026
Manufactured product of sxtchina.com

To filter out overvalued assets, investors compare market value with net assets to determine the extent of the equity premium. Analyzing the price-to-book ratio allows for an assessment of the asset quality of China SXT Pharmaceuticals (SXTC), where a diversified portfolio of phytopharmaceuticals and an extensive distribution network justify the market premium while mitigating regulatory pressure risks.

Competitor analysis

HLN: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio kenvue.com|Market Value to Book Value Ratio Verona Pharma|Jyong Biotech Limited - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio LGND|AMRX (Amneal Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|Market Capitalization to Book Value Ratio alvotech.com ALVO|LQDA - Market Value to Book Value Ratio|Market Value to Book Value GLPG (Galapagos N.V.)|ANI Pharma (ANIP) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Afrezza|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com|Market Cap to Net Assets Ratio SPRY (ARS Pharmaceuticals, Inc.)|TBPH (Theravance Biopharma Inc) - Market Value to Book Value|Market Value to Book Value Ratio Aquestive Pharma AQST|scPharmaceuticals, Inc. (SCPH) - Market-to-Book Ratio|TECX: Market Cap to Net Assets Ratio|tonixpharma.com - Market Cap to Book Value Multiple|EPRX: Market Capitalization to Book Value Ratio|BioHarvest Sciences, Inc. - Market Value to Book Value|EXOZ (Invizyne Technologies, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Oramed Pharma ORMP|Market Value to Book Value Ratio Entera Bio Ltd. (ENTX)|HYFT (ipatherapeutics.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio ABVC (ABVC BioPharma, Inc.)|CPIX - Market Cap to Net Assets Ratio|Quantum BioPharma Limited - Market Capitalization to Book Value Ratio|Market Value to Book Value FGEN (FibroGen Corporation)|TELO: Market Capitalization to Book Value Ratio|RANI - Market Capitalization to Book Value|Market Value to Book Value Ratio Synergy CHC Corp.|Capitalization to Book Value Ratio RLYB (Rallybio Corp.)|Market Capitalization to Book Value Ratio LEXX|Market Capitalization to Book Value Ratio Pulmatrix Corporation (PULM)|Pheton Holdings - Market Cap to Net Assets Ratio|Market Value to Book Value APM|LYRA - Market Value to Book Value Ratio|Market Capitalization to Book Value impactbiomedinc.com IBO|TNFA (tnfpharma.com) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio YCBD|Market Cap to Net Assets Ratio PRFX|CYTO (Auris Medical) - Market Cap to Book Value Multiple|Market Cap to Net Assets Ratio LIPO (Lipella Pharmaceuticals, Inc.)|OPTN (OptiNose Inc) - Market Value to Book Value|Market Value to Book Value Ratio Pieris PIRS|PROC (Procaps Group Corp) - Market Capitalization to Net Assets|Petros Pharmaceuticals - Market Capitalization to Book Value Ratio|Market Value to Book Value QLI (qlsyy.net)|SLRN: Market Capitalization to Book Value Ratio|TFF Pharmaceuticals Inc. (TFFP) - Market Capitalization to Book Value Ratio